This is a multicenter, double-blind, randomized controlled clinical trial to get high - level evidence on minocycline's efficacy and safety（100mg/d, 200mg/d) for Retinitis pigmentosa and to find the optimal treatment dose.
Age should be between 18 and 60 years old.
Clinically diagnosed with retinitis pigmentosa, characterized by reduced electroretinogram (ERG) responses and constricted visual fields.
In at least one eye, the amplitude of the 30Hz flicker ERG under photopic conditions should not be lower than 0 microvolts.
The best-corrected visual acuity (BCVA, ETDRS) in both eyes should not be lower than 0.
Allergic to tetracycline antibiotics.
Pregnant or breastfeeding.
Syndromic retinitis pigmentosa.
Currently taking tetracycline antibiotics or any medications that may have adverse interactions with minocycline.